GIFLF News and Press, Grifols SA Barcelona From 02/10/22

Grifols currently trading at a 30% discount to European specialty pharma. Biotest AG Investment analysis. Biotest R&D not priced in. For further details see: Grifols: Short-Term Turbulence But Long-Term Upside

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

Grifols outlines some promising new initiatives and financial targets at its latest Capital Markets Day. The most notable shift this time around was the R&D/innovation focus, which should boost the longer-term growth outlook. With the valuation discount to CSL widening to unwa...

The following slide deck was published by Grifols, S.A. in conjunction with this event. For further details see: Grifols presents at 2021 investor and analyst day - slideshow

Grifols operates in the very attractive and lucrative plasma business. The plasma-supply chain has been disrupted by the pandemic but the situation should normalize with the vaccination. Even though some new medicines could potentially disrupt the market, we believe related fears ...

DRACO GLOBAL's value proposition is to invest in the best of two worlds: mega-caps known to all, and the other extreme, unknown micro-caps with nil or low analyst coverage. We look for a scalable business model, the existence of long-term secular growth, attractive sector structure, p...

Investment Thesis CSL Limited ( CSLLY ) has yet to fully recover from the plasma shortages experienced during the lockdowns. The impact on production is likely to materialize just as elective surgeries resume. The influenza vaccine sales can pick up the slack as fears mount over a flu outb...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros's 13F stock portfolio on a quarterly basis. It is based on George Soros's regulatory 13F Form filed on 08/14/2020. Please visit our Tracking Soros Fund Management Holdings article for an ...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros’s 13F stock portfolio on a quarterly basis. It is based on George Soros’s regulatory 13F Form filed on 05/15/2020. Please visit our Tracking Soros Fund Management Holdings ar...

New York City, NY: April 09, 2020 – Recent Research and Future Market Potential of Automated Blood Processing Equipment Market in Global Industry: 2020 Research and New Innovations in Pharmaceuticals and Healthcare Sector. The prime objective of the report is to offer updates and inform...